Stress chaperone mortalin contributes to epithelial-to-mesenchymal transition and cancer metastasis

Cancer Research

Volumn 76, Issue 9, 2016, Pages 2754-2765

  Na, Youjin ^a,b   Kaul, Sunil C ^a   Ryu, Jihoon ^a   Lee, Jung Sun ^b   Ahn, Hyo Min ^a,b   Kaul, Zeenia ^c   Kalra, Rajkumar S ^a   Li, Ling ^a   Widodo, Nashi ^d   Yun, Chae Ok ^b   Wadhwa, Renu ^a  

^a NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^b Hanyang University   (South Korea)

^c OHIO STATE UNIVERSITY   (United States)

^d BRAWIJAYA UNIVERSITY   (Indonesia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CHAPERONE; CYTOKERATIN 14; CYTOKERATIN 18; CYTOKERATIN 8; FIBRONECTIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; JANUS KINASE; MORTALIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAT PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ARTICLE; BREAST CANCER CELL LINE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FOCAL ADHESION; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

EID: 84969565352     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-2704     Document Type: Article

References (50)

1. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000;2: 76-83.
2. Wang Y, Shi J, Chai K, Ying X, Zhou BP. The role of snail in EMT and tumorigenesis. Curr Cancer Drug Targets 2013;13:963-72.
3. Mallini P, Lennard T, Kirby J, Meeson A. Epithelial-to-mesenchymal transition: what is the impact on breast cancer stem cells and drug resistance. Cancer Treat Rev 2014;40:341-8.
4. Yi BR, Kim TH, Kim YS, Choi KC. Alteration of epithelial-mesenchymal transition markers in human normal ovaries and neoplastic ovarian cancers. Int J Oncol 2015;46:272-80.
5. Mironchik Y, Winnard PTJr, Vesuna F, Kato Y, Wildes F, Pathak AP, et al. Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. Cancer Res 2005;65:10801-9.
6. Tania M, Khan MA, Fu J. Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumour Biol 2014;35:7335-42.
7. Su J, Yin X, Zhou X, Wei W, Wang Z. The functions of F-box proteins in regulating the epithelial to mesenchymal transition. Curr Pharm Des 2015;21:1311-7.
8. Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 2010;15:117-34.
9. Xiong X, Wang Y, Liu C, Lu Q, Liu T, Chen G, et al. Heat shock protein 90beta stabilizes focal adhesion kinase and enhances cell migration and invasion in breast cancer cells. Exp Cell Res 2014;326:78-89
10. Bokhari AA, Syed V. Inhibition of transforming growth factor-beta (TGFbeta) signaling by Scutellaria baicalensis and Fritillaria cirrhosa extracts in endometrial cancer. J Cell Biochem 2015;116:1797-805.
11. Zarzynska JM. Two FACes of TGF-beta1 in breast cancer. Mediators Inflamm 2014;2014:141747.
12. Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW, et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 2011;13:317-23.
13. Hiscox S, Morgan L, Barrow D, Dutkowskil C, Wakeling A, Nicholson RI, et al. Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). Clin Exp Metastasis 2004;21:201-12.
14. Krasnapolski MA, Todaro LB, de Kier Joffe EB. Is the epithelial-to-mesenchymal transition clinically relevant for the cancer patient? Current Pharm Biotechnol 2011;12:1891-9.
15. Zhang P, Liu H, Xia F, Zhang QW, Zhang YY, Zhao Q, et al. Epithelialmesenchymal transition is necessary for acquired resistance to cisplatin and increases the metastatic potential of nasopharyngeal carcinoma cells. Int J Mol Med 2014;33:151-9.
16. Wadhwa R, Takano S, Kaur K, Deocaris CC, Pereira-Smith OM, Reddel RR, et al. Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis. Int J Cancer 2006;118:2973-80.
17. Lu WJ, Lee NP, Kaul SC, Lan F, Poon RT, Wadhwa R, et al. Mortalin-p53 interaction in cancer cells is stress dependent and constitutes a selective target for cancer therapy. Cell Death Differ 2011;18:1046-56.
18. Lu WJ, Lee NP, Kaul SC, Lan F, Poon RT, Wadhwa R, et al. Induction of mutant p53-dependent apoptosis in human hepatocellular carcinoma by targeting stress protein mortalin. Int J Cancer 2011;129:1806-14.
19. Ando K, Oki E, Zhao Y, Ikawa-Yoshida A, Kitao H, Saeki H, et al. Mortalin is a prognostic factor of gastric cancer with normal p53 function. Gastric Cancer 2014;17:255-62.
20. Wadhwa R, Takano S, Robert M, Yoshida A, Nomura H, Reddel RR, et al. Inactivation of tumor suppressor p53 by mot-2, a hsp70 family member. J Biol Chem 1998;273:29586-91.
21. Ma Z, Izumi H, Kanai M, Kabuyama Y, Ahn NG, Fukasawa K. Mortalin controls centrosome duplication via modulating centrosomal localization of p53. Oncogene 2006;25:5377-90.
22. Kaul SC, Aida S, Yaguchi T, Kaur K, Taira K, Wadhwa R, et al.. Activation of wild type p53 function by its mortalin-binding cytoplasmically localizing carboxy-terminus peptides. J Biol Chem 2005;280:39373-9.
23. Ryu J, Kaul Z, Yoon AR, Liu Y, Yaguchi T, Na Y, et al. Identification and functional characterization of nuclear mortalin in human carcinogenesis. J Biol Chem 2014;289:24832-44.
24. Wadhwa R,Ando H, Kawasaki H, Taira K, Kaul SC. Targeting mortalin using conventional and RNA-helicase-coupled hammerhead ribozymes. EMBO Rep 2003;4:595-601.
25. Yoo JY, Ryu J, Gao R, Yaguchi T, Kaul SC, Wadhwa R, et al. Tumor suppression by apoptotic and anti-angiogenic effects of mortalin-targeting adeno-oncolytic virus. J Gene Med 2010;12:586-95.
26. Benbrook DM, Nammalwar B, Long A, Matsumoto H, Singh A, Bunce RA, et al. SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres. Invest New Drugs 2014;32:412-23.
27. Sane S, Abdullah A, Boudreau DA, Autenried RK, Gupta BK, Wang X, et al. Ubiquitin-like (UBX)-domain-containing protein,UBXN2A, promotes cell death by interfering with the p53-Mortalin interactions in colon cancer cells. Cell Death Dis 2014;5:e1118
28. Yi X, Luk JM, Lee NP, Peng J, Leng X, Guan XY, et al. Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence. Mol Cell Proteomics 2008;7:315-25.
29. Chen J, Liu WB, Jia WD, Xu GL, Ma JL, Huang M, et al. Overexpression of Mortalin in hepatocellular carcinoma and its relationship with angiogenesis and epithelial to mesenchymal transition. Int J Oncol 2014;44:247-55.
30. Yoo JY, Kim JH, Kim J, Huang JH, Zhang SN, Kang YA, et al. Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition. Gene Ther 2008;15: 635-51.
31. Vlachos IS, Kostoulas N, Vergoulis T, Georgakilas G, ReczkoM,Maragkakis M, et al. DIANA miRPath v. 2. 0: investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res 2012;40:W498-504.
32. Chang JT, Nevins JR. GATHER: a systems approach to interpreting genomic signatures. Bioinformatics 2006;22:2926-33
33. Draghici S, Khatri P, Tarca AL, Amin K, Done A, Voichita C, et al. A systems biology approach for pathway level analysis. Genome Res 2007;17:1537-45.
34. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000;28:27-30.
35. Wadhwa R, Sugihara T, Yoshida A, Nomura H, Reddel RR, Simpson R, et al. Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. Cancer Res 2000;60:6818-21.
36. Deocaris CC, Widodo N, Shrestha BG, Kaur K, Ohtaka M, Yamasaki K, et al. Mortalin sensitizes human cancer cells to MKT-077-induced senescence. Cancer Lett 2007;252:259-69.
37. Wadhwa R, Ryu J, Ahn HM, Saxena N, Chaudhary A, Yun CO, et al. Functional significance of point mutations in stress chaperone mortalin and their relevance to Parkinson disease. J Biol Chem 2015;290:8447-56.
38. Yang L, Guo W, Zhang Q, Li H, Liu X, Yang Y, Zuo J, et al. Crosstalk between Raf/MEK/ERK and PI3K/AKT in suppression of Bax conformational change by Grp75 under glucose deprivation conditions. J Mol Biol 2011;414:654-66.
39. Smith G, Ng MTH, Shepherd L, Herrington CS, Gourley C, Ferguson MJ, et al. Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer. Br J Cancer 2012;107:1327-36.
40. Shi H, Fu C,Wang W, Li Y,DuS, Cao R, et al. The FGF-1-specific single-chain antibody scFv1C9 effectively inhibits breast cancer tumour growth and metastasis. J Cell Mol Med 2014;18:2061-70.
41. Mizukoshi E, Suzuki M, Loupatov A, Uruno T, Hayashi H, Misono T, et al. Fibroblast growth factor-1 interacts with the glucose-regulated protein GRP75/mortalin. Biochem J 1999;343:461-6.
42. Mizukoshi E, Suzuki M, Misono T, Loupatov A, Munekata E, Kaul SC, et al. Cell-cycle dependent tyrosine phosphorylation on mortalin regulates its interaction with fibroblast growth factor-1. Biochem Biophys Res Commun 2001;280:1203-9.
43. Lu W, Xu Z, Zhang M, Zuo Y. MiR-19a promotes epithelial-mesenchymal transition through PI3K/AKT pathway in gastric cancer. Int J Clin Exp Pathol 2014;7:7286-96.
44. Wang Y, Shi J, Chai K, Ying X, Zhou BP. The role of snail in EMT and tumorigenesis. Curr Cancer Drug Targets 2013;13:963-72.
45. Wang H, Xu L, Zhu X, Wang P, Chi H, Meng Z, et al.. Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma. Oncol Rep 2014;32: 1465-72.
46. Ohtsuka R, Abe Y, Fujii T, Yamamoto M, Nishimura J, Takayanagi R, et al. Mortalin is a novel mediator of erythropoietin signaling. Eur J Haematol 2007;79:114-25.
47. Vandermoere F, El Yazidi-Belkoura I, Demont Y, Slomianny C, Antol J, Lemoine J, et al. Proteomics exploration reveals that actin is a signaling target of the kinase Akt. Mol Cell Proteomics 2007;6:114-24.
48. Moustakas A, Heldin P. TGFbeta and matrix-regulated epithelial to mesenchymal transition. Biochim Biophys Acta 2014;1840:2621-34.
49. Makki J, Myint O, Wynn AA, Samsudin AT, John DV. Expression distribution of cancer stem cells, epithelial to mesenchymal transition, and telomerase activity in breastcancer and their association with clinicopathologic characteristics. Clin Med Insights Pathol 2015;8: 1-16.
50. Gao R, Yu Y, Inoue A, Widodo N, Kaul SC, Wadhwa R. Heterogeneous nuclear ribonucleoprotein K (hnRNP-K) promotes tumor metastasis by induction of genes involved in extracellular matrix, cell movement, and angiogenesis. J Biol Chem 2013;288:15046-56.